Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854383 | 1.00 | MAPT (0.56) | MAPTKLKB1CAPN1ALDH1A1DHODH | |
| SCHEMBL21854260 | 0.94 | MAPT (0.54) | MAPTKLKB1CAPN1ALDH1A1DHODH | |
| SCHEMBL20027980 | 0.94 | MAPT (0.54) | MAPTKLKB1CAPN1ALDH1A1DHODH | |
| SCHEMBL21854298 | 0.94 | MAPT (0.56) | MAPTKLKB1CAPN1ALDH1A1DHODH | |
| SCHEMBL20027975 | 0.94 | MAPT (0.56) | MAPTKLKB1CAPN1ALDH1A1DHODH | |
| SCHEMBL20027971 | 0.93 | MAPT (0.52) | MAPTKLKB1CAPN1ALDH1A1CTSS | |
| SCHEMBL21854041 | 0.93 | MAPT (0.52) | MAPTKLKB1CAPN1ALDH1A1CTSS | |
| SCHEMBL20027970 | 0.93 | MAPT (0.52) | MAPTKLKB1CAPN1ALDH1A1DHODH | |
| SCHEMBL21854080 | 0.93 | MAPT (0.52) | MAPTKLKB1CAPN1ALDH1A1DHODH | |
| SCHEMBL20027978 | 0.93 | MAPT (0.52) | MAPTKLKB1CAPN1ALDH1A1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885KLKB1 3617/4885CAPN1 3/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885KLKB1 3617/4885CAPN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.